29 Emmons Drive
286 articles with Soligenix
Analyst Jason McCarthy, PhD of Maxim Group updated coverage on Soligenix, Inc. on December 6, 2018. For more information, please visit www.maximgrp.com.
Soligenix Announces Publication of Scientific Review Discussing Clinical Applications of Innate Defense Regulator Technology
Highlights Potential for Treating Multiple Diseases with Dusquetide and Related IDR Analogs
Soligenix Selected to Present RiVax® Data at the Fourth International Conference on Vaccines Research & Development in Baltimore, Maryland
Soligenix, Inc. announced that Dr. Oreola Donini, Chief Scientific Officer, will be presenting data from the ricin toxin vaccine (RiVax®) program describing development of the vaccine under the Food and Drug Administration (FDA) Animal Rule.
Soligenix, Inc. announced today its recent accomplishments and financial results for the third quarter ended September 30, 2018.
Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell Lymphoma
Soligenix, Inc. announced today it has received a positive recommendation from the independent Data Monitoring Committee (DMC) to continue enrolling into the Company's Phase 3 "Fluorescent Light Activated Synthetic Hypericin" (FLASH) study for SGX301 (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL).
Soligenix Announces Poster Presentations of its Ricin Vaccine and Dusquetide Oral Mucositis Programs at the 2018 NORD Rare Diseases and Orphan Products Breakthrough Summit
Soligenix, Inc. announced today that it has been invited to present results from two of its development programs at National Organization for Rare Disorders' (NORD's) Rare Diseases and Orphan Products Breakthrough Summit on October 15-16, 2018 in Washington, DC.
Dr. Oreola Donini, Senior Vice President and Chief Scientific Officer, discusses the Company's ricin toxin vaccine with ROI-NJ.
NIH selects Soligenix's SGX942 in the Treatment of Oral Mucositis for the Commercialization Accelerator Program
The SGX942 program has been specifically selected by the NIH for the Commercialization Transition Track
Soligenix, Inc. announced today that its Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation at the 25th Annual NewsMakers in the Biotech Industry on Friday, September 7 at 11:30AM ET.
Soligenix Announces Publication of Positive Long-Term Data Supporting Thermostability and Conformational Integrity of the RiVax® Ricin Toxin Vaccine
Soligenix, Inc. announced today publication of extended stability studies for RiVax® showing up to 100% protection in mice even after 12 months storage at 40 degrees Celsius
Soligenix to Present at the 2018 ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
Soligenix, Inc. announced today that Dr. Oreola Donini, Chief Scientific Officer, will be presenting preclinical and clinical data illustrating the potential utility of the Innate Defense Regulator technology in the treatment of infectious disease in a poster session at the upcoming European Society of Clinical Microbiology and Infectious Diseases / American Society of Microbiology Conference
Active Ingredient in SGX301 for the Treatment of Cutaneous T-Cell Lymphoma
Soligenix, Inc. announced its recent accomplishments and financial results for the second quarter ended June 30, 2018.
Soligenix Announces a RiVax® Program Presentation at the 31st Annual Congress on Vaccines, Clinical Trials & B2B in Vancouver, Canada
Soligenix, Inc. announced that Dr. Oreola Donini, Chief Scientific Officer, will be presenting data from the ricin toxin vaccine (RiVax®) program describing potential immune correlates of protection to facilitate vaccine approval under the Food and Drug Administration (FDA) Animal Rule.
Soligenix intends to leverage Mr. Pearson's extensive business and investing experience
Soligenix - Drivng Towards Key Inflection Points with Two Pivotal Phase 3 Clinical Trials Provides Mid-year 2018 Update
Company provides mid-year update and guidance [19-July-2018] PRINCETON, N.J., July 19, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its Pres
Soligenix, Inc. announced that it has received notice of allowance for European (application No. 12786638.2) and Canadian (application No. 2836273) patent applications further extending protection around ThermoVax®
Soligenix, Inc. (Nasdaq: SNGX), announced today the closing of its previously announced underwritten public offering of 7,766,990 shares.
The offering is expected to close on July 2, 2018, subject to customary closing conditions.
Soligenix Announces Poster at the 2018 American Society of Microbiology Microbe Conference in Atlanta, Georgia
Soligenix, Inc. announced that Dr. Oreola Donini, Chief Scientific Officer, will be presenting preclinical and clinical data illustrating the potential utility of the Innate Defense Regulator technology in the treatment of infectious disease at the upcoming American Society of Microbiology Microbe Conference.